Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: A reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics

Journal of Clinical Psychiatry

Volumn 72, Issue 12, 2011, Pages 1685-1690

  Calarge, Chadi A ^a   Ellingrod, Vicki L ^b   Zimmerman, Bridget ^c   Bliziotes, Michael M ^d   Schlechte, Janet A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PROLACTIN; PSYCHOSTIMULANT AGENT; RISPERIDONE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

5 HTTLPR GENE; ADOLESCENT; ANTHROPOMETRY; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; BONE DENSITY; CALCIUM INTAKE; CAUCASIAN; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISRUPTIVE BEHAVIOR; DUAL ENERGY X RAY ABSORPTIOMETRY; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERPROLACTINEMIA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; PHARMACOGENETICS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; PUBERTY; RADIUS; SCHOOL CHILD; TIC; TRABECULAR BONE; TREATMENT DURATION; UNITED STATES;

EID: 84555220533     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06198     Document Type: Article

References (32)

1. Delate T, Gelenberg AJ, Simmons VA, et al. Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002. Psychiatr Serv. 2004;55(4):387-391. (Pubitemid 38445583)
2. Birmaher B, Brent D, Bernet W, et al. AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1503-1526.
3. Connolly SD, Bernstein GA; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2007;46(2):267-283.
4. Emslie GJ, Kennard BD, Mayes TL, et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry. 2008;165(4):459-467. (Pubitemid 351694289)
5. Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166(5):591-598.
6. Haney EM, Warden SJ. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact. 2008;8(2):133-145.
7. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785-795.
8. Calarge CA, Zimmerman B, Xie D, et al. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry. 2010;71(3):338-347.
9. Battaglino R, Fu J, Späte U, et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res. 2004;19(9):1420-1431. (Pubitemid 41094343)
10. Gustafsson BI, Thommesen L, Stunes AK, et al. Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem. 2006;98(1):139-151.
11. Bliziotes MM, Eshleman AJ, Zhang XW, et al. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone. 2001;29(5):477-486. (Pubitemid 33026469)
12. Warden SJ, Robling AG, Sanders MS, et al. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology. 2005;146(2):685-693. (Pubitemid 40129824)
13. Calarge C, Kuperman S. Fluoxetine for depression relapse prevention. J Am Acad Child Adolesc Psychiatry. 2005;44(10):966-967, author reply 967-968.
14. Nilsson M, Joliat MJ, Miner CM, et al. Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2004;14(3):412-417. (Pubitemid 39473126)
15. Uher R, McGuffin P. The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. Mol Psychiatry. 2008;13(2):131-146.
16. Smith GS, Lotrich FE, Malhotra AK, et al. Effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology. 2004;29(12):2226-2234. (Pubitemid 39578914)
17. Calarge CA, Ellingrod VL, Acion L, et al. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009;19(5):373-382.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
19. Block G, Murphy M, Roullet JB, et al. Pilot validation of a FFQ for children 8-10 years. Abstract presented at: Fourth International Conference On Dietary Assessment Methods; September 17-20, 2000; Tucson, Arizona.
20. Slemenda CW, Peacock M, Hui S, et al. Reduced rates of skeletal remodeling are associated with increased bone mineral density during the development of peak skeletal mass. J Bone Miner Res. 1997;12(4):676-682. (Pubitemid 27155228)
21. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics. 2002;109(1):45-60. (Pubitemid 34049426)
22. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996;66(6):2621-2624. (Pubitemid 26159101)
23. Bell NH, Shary J, Stevens J, et al. Demonstration that bone mass is greater in black than in white children. J Bone Miner Res. 1991;6(7):719-723.
24. Janz KF, Lutuchy EM, Wenthe P, et al. Measuring activity in children and adolescents using self-report: PAQ-C and PAQ-A. Med Sci Sports Exerc. 2008;40(4):767-772. (Pubitemid 351416854)
25. Risch N, Herrell R, Lehner T, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA. 2009;301(23):2462-2471.
26. Bliziotes M, Eshleman A, Burt-Pichat B, et al. Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone. 2006;39(6):1313-1321. (Pubitemid 44827920)
27. Weintrob N, Cohen D, Klipper-Aurbach Y, et al. Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med. 2002;156(7):696-701. (Pubitemid 34756000)
28. Aitchison K, Huezo-Diaz P, Williamson R, et al. Genetic association data from GENDEP, a multicentre European study. Am J Med Genetics. 2006;141B(7):690.
29. Saag K. Mend the mind, but mind the bones!: balancing benefits and potential skeletal risks of serotonin reuptake inhibitors. Arch Intern Med. 2007;167(12):1231-1232. (Pubitemid 46998492)
30. Yirmiya R, Bab I. Major depression is a risk factor for low bone mineral density: a meta-analysis. Biol Psychiatry. 2009;66(5):423-432.
31. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68(1):29-39.
32. Bradney M, Karlsson MK, Duan Y, et al. Heterogeneity in the growth of the axial and appendicular skeleton in boys: implications for the pathogenesis of bone fragility in men. J Bone Miner Res. 2000;15(10):1871-1878.